Atractylenolide I Inhibits the Growth of Esophageal Cancer Cells by Inhibiting the Wnt/β-Catenin Pathway
This study indicates that Atractylenolide I is an efficient lead compound for the treatment of esophageal cancer, providing a theoretical basis for further clinical development and application of Atractylenolide I.
Authors
- Dong Tang (ORCID: https://orcid.org/0009-0009-6687-3617)
- Na Niu (ORCID: https://orcid.org/0009-0006-0395-336X)
- Yong Li (ORCID: https://orcid.org/0000-0002-8910-9787)
- Chunlei Yu (ORCID: https://orcid.org/0000-0002-2934-2122)
- Maowei Lian
- Xiaocong Xiang (ORCID: https://orcid.org/0000-0003-4950-1247)
- Li Xu (ORCID: https://orcid.org/0000-0003-4950-0789)
- Lihua Cao (ORCID: https://orcid.org/0009-0002-0019-3968)
- Yunxiang Zhang (ORCID: https://orcid.org/0000-0002-6635-6443)
Institutions
- North Sichuan Medical University (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2025-02-21
- DOI
- https://doi.org/10.2174/0118715206366543250213071529
- Citations
- 2
- Primary Topic
- Phytochemical Studies and Bioactivities
- Type
- article
- Field-Weighted Citation Impact
- 1.61